CagriSema Explained: Semaglutide Plus Cagrilintide

CagriSema is an investigational once-weekly injection that combines two medicines: semaglutide, which activates the GLP-1 receptor (the same ingredient as Wegovy and Ozempic), and cagrilintide, a long-acting analogue of the hormone amylin. The idea is to influence appetite and fullness through two different hormone pathways at once.

As of October 2026, CagriSema is not FDA-approved. Novo Nordisk submitted it to the FDA for chronic weight management in December 2025 and says it expects a US decision in the fourth quarter of 2026. A submission means the regulator is reviewing the evidence; it isn't a green light.

Why combine two mechanisms?

Amylin is a hormone released alongside insulin after meals. It slows stomach emptying, dampens the post-meal rise in glucagon and adds to feelings of fullness. GLP-1 signaling affects appetite and blood sugar through a separate receptor. Researchers wanted to know whether using both together would do more than either alone. That's a reasonable hypothesis, and trials are what test it. (For a deeper look, see what amylin is and how it differs from GLP-1.)

What have the trials found?

Peer-reviewed Phase 3 results (NEJM, 2025), dose 2.4 mg of each medicine weekly, 68 weeks:

• REDEFINE 1: 3,417 adults with obesity or overweight without diabetes. Average weight change was −20.4% with CagriSema versus −3.0% with placebo. Gastrointestinal side effects (nausea, vomiting, diarrhea, constipation, abdominal pain) affected 79.6% on CagriSema versus 39.9% on placebo, mostly mild to moderate and temporary.
• REDEFINE 2: 1,206 adults with obesity or overweight and type 2 diabetes. Average weight change was −13.7% versus −3.4% with placebo, and gastrointestinal side effects affected 72.5% versus 34.4%.

Notice the gap between those two trials: people with type 2 diabetes often lose less weight on these medicines on average, which is one reason trial populations matter so much.

Company-reported results (not yet in full peer-reviewed papers):

• REDEFINE 4 (February 2026): an open-label, 84-week head-to-head trial in 809 adults with obesity compared CagriSema 2.4/2.4 mg with tirzepatide 15 mg. It did not meet its main goal of showing CagriSema was non-inferior to tirzepatide. Average weight change was −20.2% versus −23.6% when counting everyone regardless of whether they stayed on treatment.
• REIMAGINE 5 and REDEFINE 9 (September 2026): Novo reported topline results in type 2 diabetes (against tirzepatide 5 mg, 60 weeks) and in overweight or obesity (lower CagriSema doses against placebo, 68 weeks). These are sponsor announcements, so full details are still to come.

How to read CagriSema headlines

Check which trial a number comes from, who was enrolled, how long it lasted, which dose was used and what the comparison was. Also check the "estimand": some figures assume everyone stayed on treatment, which makes results look larger than counting everyone who started. And remember that results from separate trials aren't a head-to-head comparison.

Can you get CagriSema now?

Not as an approved prescription product in the US. Regulatory decisions can also differ between countries. Be wary of any website or clinic selling "CagriSema" or cagrilintide: an investigational product bought online isn't the same as the medicine studied in trials, and there's no way to verify what's inside. Here's more on why investigational drugs aren't the same as approved medicines.

The takeaway

CagriSema shows how the field is moving toward combinations that act on more than one appetite pathway. Its results are substantial, but it fell short of tirzepatide in their head-to-head trial, and the FDA decision is still pending. It's worth following, not something to treat as already on the pharmacy shelf.